Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + LY2157299 in metastatic cancer and unresectable pancreatic cancer
2011-000211-64Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galunisertib and gemcitabine in pancreatic cancer (PC) and metastasis, sponsored by Eli Lilly and Company. Primary endpoint: Maximum tolerated dose and recommended Phase 2 dose of LY2157299 in combination with gemcitabine (Phase 1b). Started Aug 2011; status: completed.
02
Drugs
galunisertibgemcitabine
03
Conditions
pancreatic cancer (PC)metastasis
Beyond the preview
Go deeper on 2011-000211-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000211-64.